Pertaprime: An investigator-driven phase II-III randomised, observer-blind, controlled trial to demonstrate non-inferior immunogenicity of Pertagen in comparison to Boostrix in healthy young Australian adults aged 18-25 years

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pertussis acellular vaccine (Primary) ; DTaP vaccine
Indications Pertussis
Focus Pharmacodynamics
Acronyms Pertaprime

Most Recent Events

04 Nov 2021 Planned End Date changed from 29 Jul 2022 to 30 Sep 2022.
18 Jun 2021 Planned initiation date changed from 6 Jan 2020 to 28 Feb 2020.
18 Jun 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight